[1]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86-88，92.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Journal of Medical Information,2019,32(03):86-88，92.[doi:10.3969/j.issn.1006-1959.2019.03.026]
点击复制

肝硬化合并门静脉血栓形成的危险因素分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年03期
页码:
86-88，92
栏目:
论著
出版日期:
2019-02-01

文章信息/Info

Title:
Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis
文章编号:
1006-1959（2019）03-0086-04
作者:
赵华莹; 李运泽; 韦天灵; 龙 颖; 莫双阳
（柳州市人民医院消化内科，广西 柳州，545006）
Author(s):
ZHAO Hua-ying; LI Yun-ze; WEI Tian-ling; LONG Ying; MO Shuang-yang
(Department of Gastroenterology,Liuzhou People's Hospital,Liuzhou 545006,Guangxi,China)
关键词:
肝硬化; 门静脉血栓; D-二聚体; 门静脉内径宽度; 血红蛋白
Keywords:
Liver cirrhosis; Portal venous thrombosis; D-dimer; Portal vein width; Hemoglobin
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2019.03.026
文献标志码:
A
摘要:
目的 探讨肝硬化并发门静脉血栓形成的危险因素。方法 选取我院2013年1月~2018年1月确诊的肝硬化患者69例，其中经腹部CT或腹部超声诊断为门静脉血栓患者24例设为血栓组，未发生血栓患者45例设为对照组。回顾性分析肝硬化门静脉血栓患者与肝硬化非血栓患者的年龄、性别、肝硬化病因；比较两组患者的D-二聚体、白细胞计数（WBC）、血红蛋白（Hb）、血小板（PLT）、肌酐（Cr）、凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、纤维蛋白原（Fib）、血清总胆红素（TBIL）、直接胆红素（DBIL）、白蛋白（ALB）、丙氨酸氨基转移酶（ALT）、天门冬氨基转移酶（AST）、γ-谷氨酰转肽酶（GGT）、血氨浓度、门静脉内径宽度（MVP）、脾脏厚度、脾切除史、有无合并食管胃底静脉曲张出血及腹腔积液。结果 两组性别、年龄、肝硬化病因、腹腔积液并发症比较，差异无统计学意义（P＞0．05），两组食管静脉曲张破裂出血并发症比较，差异有统计学意义（P＜0．05）。血栓组腹部超声或螺旋CT增强扫描显示：门静脉主干血栓22例（91.67%）（1例合并肠系膜上静脉血栓，6例合并左/右门静脉分支，1例合并左/右门静脉分支及肠系膜上静脉血栓），单纯位于左/右门静脉分支2例（8.33%）；两组患者中D-二聚体、AST、ALT、ALB、PTA、PLT差异存在统计学意义（P＜0.05）；Logistic回归模型分析显示，D-二聚体、门静脉内径宽度、Hb是肝硬化门静脉血栓形成的独立危险因素（P＜0.05）。结论 肝硬化患者应加强对患者D-二聚体、血红蛋白、门静脉内径宽度的监测，有助于患者疾病早期诊断和治疗。
Abstract:
Objective To investigate the risk factors of patients with cirrhosis complicated by portal venous thrombosis．Methods 69 patients with liver cirrhosis diagnosed in our hospital from January 2013 to January 2018 were selected, among which,24 patients with portal vein thrombosis diagnosed by abdominal CT or abdominal ultrasound were divided into the thrombosis group,and 45 patients without thrombosis were divided into the control group.The age, sex and etiology of cirrhotic portal vein thrombosis and non-thrombotic cirrhosis were analyzed retrospectively.The D-dimer,White blood cell count (WBC),hemoglobin (Hb),platelets (PLT),creatinine (Cr),prothrombin time (PT),activated partial thrombin time (APTT),fibrinogen (Fib),serum total bilirubin (TBIL),direct bili-rubin (DBIL),albumin (ALB),alanine aminotransferase (ALT),aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT),blood ammonia concentration,history of splenectomy，portal vein width (MPV)，Thickness of spleen，esophageal vaficeal bleeding，ascites were compared between two groups.Results There were no significant difference in sex，age，causes of cirrhosis between thrombosis group and control group（P＞0.05）.The complications of esophageal variceal bleeding in the two groups were significantly different (P<0.05).Abdominal ultrasound or spiral CT enhanced scan showed 22 cases (91.67%) of portal vein thrombosis in thrombus group(1 case with superior mesenteric vein thrombosis, 6 cases with left / right portal vein branch, 1 case with left / right portal vein branch and 1 case with superior mesenteric vein thrombosis).2 cases were located in left / right portal vein branch (8.33%).There was significant difference in D-dimer and AST,ALT,ALB,PTA,PLT between the two groups (P<0.05).Logistic regression analysis showed that D-dimer, diameter width of portal vein and Hb were independent risk factors of portal vein thrombosis in liver cirrhosis (P<0.05).Conclusion The monitoring of D-dimer, hemoglobin and portal vein diameter should be strengthened in patients with liver cirrhosis, which is helpful to the early diagnosis and treatment of patients with liver cirrhosis.

参考文献/References:


[1]Ogren M,Bergqvist D,Bjorck M,et al．Portal vein thrombosis：prevalence，patient characteristics and lifetime risk:a population study based on 23，796 consecutive autopsies[J].world J Gastroenterol,2006,12(13):2115-2119．
[2]Zocco MA,Di Stasio E,De Cristofaro R,et a1.Thrombotic risk factors in patients with liver cirrhosis：correlation with MELD scoring system and portal vein thrombosis development[J].J Hepatol,2009,51(4):682-689．
[3]Qi XS,Han GH,Fan DM.Management of portal vein thrombosis in liver cirrhosis[J].Nat Rev Gastroenterol Hepatol,2014(11):435,446.
[4]Maruyama H,Okugawa H,Takahashi M,et al.De novo portal vein thrombosis in virus-related cirrhosis:predictive factors and long-term outcomes[J].Am J Gastroenterol,2013,108(4):568-574．
[5]Abdel-Razik A,Mousa N,Elhelaly R,et al.De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system[J].Eur J Gastroenterol Hepatol,2015,27(5):585-592．
[6]中华医学会肝病学分会.中华医学会感染病学分会慢性乙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015,23(12):888-905．
[7]Yogesh K,Chawla,Vijay Bodh.Portal Vein Thrombosis[J].J Clin Exp Hepatol,2015,5(1):22-40.
[8]Gardiner C,Pennaneac'h C,Walford C,et al.An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis[J].Br J Haematol,2005,128(6):842-848.
[9]Thammishetti V,Dharanipragada S,Basu D,et al,A Prospective Study of the Clinical Profile,Outcome and Evaluation of D-dimer in Cerebral Venous Thrombosis[J].Clin Diagn Res,2016,10(6):7-10.
[10]Yang S,Fan X,Ding W,et al.D-Dimer as an Early Marker of Severity in Patients With Acute Superior Mesenteric Venous Thrombosis[J].Medicine,2014,93(29):1-10.
[11]Dai J,Qi X,LiH,et al.Role of D-dimer in the Development of Portal Vein Thrombosis in Liver Cirrhosis:A Meta-analysis[J].Saudi J Gastroenterol,2015,21(3):165-174.
[12]林国帅,徐琴,赵淑一,等.肝硬化合并门静脉血栓形成的临床特点及其相关危险因素分析[J].中华肝脏病杂志,2016,24(7):513-517.
[13]池添雨,张玫.肝硬化并发静脉血栓形成的危险因素分析[J].胃肠病学和肝病学杂志,2017,26(1):17-19.
[14]王满才,田斌,王根年,等.肝硬化脾切除术后门静脉血栓形成相关因素的Meta分析[J].中华肝胆外科杂志,2014,20(12):855-861.
[15]臧立娜,邢慧慧,王嘉菲,等.肝硬化并发门静脉血栓研究进展[J].实用肝脏病杂志,2014,17(4):429-432.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Journal of Medical Information,2018,31(03):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Journal of Medical Information,2022,35(03):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(03):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[5]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(03):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[6]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[7]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Journal of Medical Information,2022,35(03):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[8]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(03):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[9]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Journal of Medical Information,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[10]曹 宇,何其顺,郭雅雯,等.延时扫描对肝硬化患者肝脏增强CT检查中动脉期时相的影响[J].医学信息,2020,33(01):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
　CAO Yu,HE Qi-shun,GUO Ya-wen,et al.Effect of Delayed Scanning on the Phase of the Middle Arterial Phase of Liver Enhanced CT in Patients with Cirrhosis[J].Journal of Medical Information,2020,33(03):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]

更新日期/Last Update: 2019-02-25